ArticlePloS one2015
Plasma Matrix Metalloproteinase-9 Levels Predict First-Time Coronary Heart Disease: An 8-Year Follow-Up of a Community-Based Middle Aged Population.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Salivary Alterations of Myeloperoxidase in Patients with Systemic Diseases: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Circulating type I collagen pro-α1 chain is inversely associated with the presence of coronary atherosclerosis in a Swedish middle-aged population.Scientific reports · 2026Article
- Prognostic Value of Matrix Metalloproteinase 9 (MMP9) in Patients Following Off-Pump Coronary Artery Bypass Grafting.Life (Basel, Switzerland) · 2025Article
- The Degrees of Coronary Heart Disease and the Degrees of New-Onset Blepharitis: A Nationwide Cohort Study.Diagnostics (Basel, Switzerland) · 2024Article
- Article
- Identification of Oxidative Stress-Related Biomarkers in Acute Myocardial Infarction.International journal of general medicine · 2023Article
- Sex-Related Differences of Matrix Metalloproteinases (MMPs): New Perspectives for These Biomarkers in Cardiovascular and Neurological Diseases.Journal of personalized medicine · 2022Review
- The Translation and Commercialisation of Biomarkers for Cardiovascular Disease-A Review.Frontiers in cardiovascular medicine · 2022Review
- Impact of MMP-9 Genetic Polymorphism and Concentration on the Development of Coronary Artery Disease in Ukrainian Population.Cardiology research and practice · 2022Article
- Altered Vascular Extracellular Matrix in the Pathogenesis of Atherosclerosis.Journal of cardiovascular translational research · 2021Review
- Effects and Mechanism of Noninvasive Positive-Pressure Ventilation in a Rat Model of Heart Failure Due to Myocardial Infarction.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- Plasma MMP-9 and TIMP-1 levels on ICU admission are associated with 30-day survival.Wiener klinische Wochenschrift · 2021Article
- History of Severe Hypoglycemia in Type 2 Diabetes Mellitus Unmasked Significant Atherosclerotic Coronary Artery Disease: A Comparative Case Control Study.Journal of the ASEAN Federation of Endocrine Societies · 2021Article
- The Role of Matrix Metalloproteinase-9 in Atherosclerotic Plaque Instability.Mediators of inflammation · 2020Review
- Article
- The frontline of immune response in peripheral blood.PloS one · 2017Article
- Measuring psychosocial factors in health surveys using fewer items.Health psychology openArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe enzyme in matrix metalloproteinase (MMP)-9 has been suggested to be an important determinant of plaque degradation. While several studies have shown elevated levels in patients with coronary heart disease, results in prospective population based studies evaluating MMP-9 in relation to first time coronary events have been inconclusive. As of today, there are four published studies which have measured MMP-9 in serum and none using plasma. Measures of MMP-9 in serum have been suggested to have more flaws than measures in plasma.
aimTo investigate the independent association between plasma levels of MMP-9 and first-time incidence of coronary events in an 8-year follow-up. MATERIAL AND
methods428 men and 438 women, aged 45-69 years, free of previous coronary events and stroke at baseline, were followed-up. Adjustments were made for sex, age, socioeconomic position, behavioral and cardiovascular risk factors, chronic disease at baseline, depressive symptoms, interleukin-6 and C-reactive protein.
results53 events were identified during a risk-time of 6 607 person years. Hazard ratio (HR) for MMP-9 after adjustment for all covariates were HR = 1.44 (1.03 to 2.02, p = 0.033). Overall, the effect of adjustments for other cardiovascular risk factors was low.
conclusionLevels of plasma MMP-9 are independently associated with risk of first-time CHD events, regardless of adjustments. These results are in contrast to previous prospective population-based studies based on MMP-9 in serum. It is essential that more studies look at MMP-9 levels in plasma to further evaluate the association with first coronary events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.